Filing Flows › Anika Therapeutics (ANIK) › Q4 2025
Anika Therapeutics (ANIK) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 3, 2026
Anika Therapeutics (ANIK) reported revenue of $30.6M for the fourth quarter 2025 (Q4 2025), 0% from a year earlier and +10% from the quarter before. Operating margin was 2.1%, net earnings $292K (1.0% of revenue).
Anika Therapeutics, Q4 2025: revenue $30.6M (0% year over year), operating margin 2.1%, net earnings $292K, operating cash flow $4.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $30.6M | +10% | 0% |
| Operating profit | $646K | — | — |
| Net earnings | $292K | — | — |
| Operating cash flow | $4.6M | -33% | +193% |
| Free cash flow | $4.0M | -20% | 15× |
What changed
Revenue was $30.6M in Q4 2025, roughly flat year over year and up 10% from the previous quarter. OEM Channel was the largest line at 57% of revenue.
Gross margin was 62.6%, up 6.7 points from a year earlier. Operating profit was $646K, a 2.1% margin (up 4.4 points year over year). Operating expenses grew 4% against flat revenue. Net earnings were $292K.
Operating cash flow was $4.6M (up 193% year over year), 1588% of net earnings. Non-cash charges added back $1.3M of depreciation and amortization and $2.5M of share-based compensation. Working capital and other items added $569K. Capital expenditures of $648K left free cash flow of $4.0M.
Questions
What was Anika Therapeutics' revenue in the fourth quarter 2025?
Anika Therapeutics (ANIK) reported revenue of $30.6M for the fourth quarter 2025 (Q4 2025), 0% from a year earlier and +10% from the quarter before.
Was Anika Therapeutics profitable in the fourth quarter 2025?
Operating profit was $646K (2.1% of revenue) and net earnings $292K.
Source: Anika Therapeutics 10-K on SEC EDGAR.